Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia

PHASE3TerminatedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

December 22, 2022

Primary Completion Date

May 5, 2025

Study Completion Date

May 5, 2025

Conditions
Respiratory InfectionPneumoniaCommunity-acquired PneumoniaAcute Respiratory Distress SyndromeCOVID-19Viral PneumoniaBacterial PneumoniaFungal Pneumonia
Interventions
DRUG

Trimodulin

IMP will be administered via IV infusion on 5 consecutive days

DRUG

Placebo (human albumin 1%)

IMP will be administered via IV infusion on 5 consecutive days

Trial Locations (64)

1090

Investigational Site #4304, Vienna

1340

Investigational Site #3201, Ottignies

1602

Investigational Site #5401, Buenos Aires

1864

Investigational Site #2702, Klerksdorp

2650

Investigational Site #3203, Edegem

2800

Investigational Site #3202, Mechelen

4020

Investigational Site #4302, Linz

4031

Investigational SIte #3603, Debrecen

5000

Investigational Site #5403, Córdoba

5100

Investigational Site #2703, Mthatha

6600

Investigational Site #2705, Plettenberg Bay

6725

Investigational Site #3601, Szeged

8301

Investigational site #2706, Kimberley

9020

Investigational Site #4303, Klagenfurt

10117

Investigational Site #4904, Berlin

28040

Investigational Site #3403, Madrid

28222

Investigational Site #3404, Madrona

30625

Investigational Site #4903, Hanover

34303

Investigational Site #9004, Istanbul

42055

Investigational Site #3305, Saint-Etienne

44892

Investigational Site #4901, Bochum

47116

Investigational Site #7002, Kaunas

61100

Investigational Site #9001, Trabzon

67091

Investigational Site #3306, Strasbourg

67098

Investigational Site #3308, Strasbourg

75020

Investigational Site #3304, Paris

75877

Investigational Site #3301, Paris

77000

Investigational Site #3303, Melun

80054

Investigational Site #3307, Salouël

81377

Investigational Site #4907, München

90122

Investigational Site #2102, Malacky

90400

Investigational Site #3302, Trévenans

95991

Investigational Site #2101, Nitra

97517

Investigational Site #2103, Banská Bystrica

X5021FPQ

Investigational Site #5402, Córdoba

83606-177

Investigational Site #5508, Campo Largo

14048-900

Investigational Site #5509, Ribeirão Preto

01323-903

Investigational Site #5511, São Paulo

18618-686

Investigational Site #5505, Botucatu

90020-090

Investigational Site #5503, Porto Alegre

90035-903

Investigational Site #5507, Porto Alegre

90610-000

Investigational Site #5506, Porto Alegre

09030-10

Investigational Site #5502, Santo André

11075-101

Investigational Site #5510, Santos

15090-000

Investigational Site #5504, São José do Rio Preto

09530-700

Investigational Site #5501, São Paulo

03048

Investogational Site #4902, Cottbus

LV-5417

Investigational Site #7102, Daugavpils

LV-1002

Investigational Site #7101, Riga

LT-44320

Investigational Site #7007, Kaunas

LT-50161

Investigational Site #7005, Kaunas

LT-92288

Investigational Site #7003, Klaipėda

LT-76231

Investigational Site #7004, Šiauliai

08661

Investigational Site #7006, Vilnius

LT-08406

Investigational Site #7001, Vilnius

4835-044

Investigational Site #3502, Guimarães

1500-650

Investogational SIte #3501, Lisbon

07101

Investigational Site #2105, Michalovce

08901

Investigational Site #2104, Svidník

0001

Investigational Site #2701, Pretoria

0002

Investigational Site #2707, Pretoria

0204

Investigational Site #2704, Pretoria

08036

Investigational Site #3401, Barcelona

06800

Investigational Site #9005, Ankara

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biotest

INDUSTRY